The Efficacy of Remimazolam on Incidence of Hypoxia During Sedated Transvaginal Oocyte Retrieval

StatusCompleted
PhaseNot applicable
SponsorDiansan Su
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Trial completed Show 7 more changesShow less
    • Primary completion date changed from estimate of Dec 20, 2026 to Sep 1, 2026
    • Study sites: 3 to 2
    • Study completion date changed from estimate of Dec 30, 2026 to Oct 1, 2026
    • Eligibility criteria expanded, about 8 words
    • Secondary endpoints: details revised at 2 of 3 entries
    • Publications: details revised at 1 of 1 entry
    • Study title shortened, about 5 words
  2. Study First Submitted
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Hypoxia is the most common adverse reaction during sedation outside the operating room.Exploring novel drug combinations to reduce the incidence of hypoxia during sedation in patients undergoing transvaginal oocyte retrieval procedures enhances patient safety and lowers perioperative adverse event rates. This multicenter, prospective, randomized, controlled clinical study will compare the hypoxia incidence rate of the remimazolam-alfentanil combination against the commonly used propofol-alfentanil combination.
Trial Details
NCT Number NCT07335536
Lead Sponsor Diansan Su
Conditions
(from sponsor)		 Hypoxia, Infertility, Infertility Assisted Reproductive Technology
Related terms Hypoxia, Infertility
Enrollment 400 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov